Sign up Australia
Proactive Investors - Run By Investors For Investors

Holista CollTech secures distribution rights for unique algae supplement

The stem-cell growth promoting algae is harvested from Klamath Lake in Oregon.
an old couple
The supplement has anti-aging properties

Holista CollTech Limited (ASX:HCT) has secured the global distribution rights for a supplement, sourced from algae found in pristine conditions in a lake in the U.S., that can enhance stem cell growth.

The Aphanizomenon Flos-aquae (AFA) algae is harvested from Klamath Lake in Oregon, which is considered to be the most pristine environment in North America after Alaska.

When consumed, the Klamax™ algae supplement is believed to enhance general wellness and anti-aging health, by promoting and supporting a normal neurological, somatic and stem-cells physiology.

The algae’s unusual properties are due in part to the fact that it grows on the surface of the lake that sits on top of a 7,700-year bed of rich volcanic ash.

Developed by scientist Dr Stefano Scoglio, the product has a high concentration of a molecule endowed with neuromodulating, immune-enhancing and neuronal stem-cell promoting activities.

Holista intends to develop oral and transdermal preparations to be sold through network marketing platform, iGalen International Inc.

In September 2017, Holista announced that it was acquiring a 47% stake in iGalen from Dr Rajen Manicka for a nominal consideration of US$1 pending shareholder approval.

iGalen has more than 12,500 distributors worldwide, and intends to enter Australia and New Zealand, in addition to the U.S., Canada, Malaysia, Singapore and Philippines.

In August 2017, Holista had secured the global rights for Emulin®, an all-natural carbohydrates manager developed by two Nobel Prize nominees.





Register here to be notified of future HCT Company articles
View full HCT profile View Profile

Holista Colltech Ltd Timeline

Newswire
September 19 2017

Related Articles

picture of addict
Thu
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
1-Operation.jpg
January 19 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
ventripoint_device.png
June 22 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use